United Therapeutics Corp UTHR
We take great care to ensure that the data presented and summarized in this overview for UNITED THERAPEUTICS Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding UTHR
View all-
Black Rock Inc. New York, NY5.47MShares$1.61 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.46MShares$1.31 Billion0.03% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.68MShares$788 Million13.34% of portfolio
-
State Street Corp Boston, MA2.23MShares$657 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.11MShares$620 Million1.04% of portfolio
-
Wellington Management Group LLP Boston, MA2.03MShares$597 Million0.12% of portfolio
-
Geode Capital Management, LLC Boston, MA1.22MShares$360 Million0.03% of portfolio
-
Aqr Capital Management LLC Greenwich, CT908KShares$268 Million0.29% of portfolio
-
Lsv Asset Management Chicago, IL902KShares$266 Million0.67% of portfolio
-
Dimensional Fund Advisors LP Austin, TX625KShares$184 Million0.05% of portfolio
Latest Institutional Activity in UTHR
Top Purchases
Top Sells
About UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Insider Transactions at UTHR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 26
2025
|
Paul A Mahon EVP & GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
11,000
-4.23%
|
$3,146,000
$286.53 P/Share
|
Jun 26
2025
|
Paul A Mahon EVP & GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+18.71%
|
$1,485,000
$135.42 P/Share
|
Jun 24
2025
|
Richard Giltner |
SELL
Open market or private sale
|
Direct |
3,036
-13.54%
|
$877,404
$289.6 P/Share
|
Jun 24
2025
|
Richard Giltner |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+18.23%
|
$875,000
$175.43 P/Share
|
Jun 24
2025
|
Nilda Mesa |
SELL
Open market or private sale
|
Direct |
645
-11.67%
|
$186,405
$289.99 P/Share
|
Jun 12
2025
|
Paul A Mahon EVP & GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
11,000
-3.61%
|
$3,069,000
$279.34 P/Share
|
Jun 12
2025
|
Paul A Mahon EVP & GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+18.71%
|
$1,485,000
$135.42 P/Share
|
Jun 09
2025
|
James Edgemond CFO AND TREASURER |
SELL
Open market or private sale
|
Direct |
12,000
-14.33%
|
$3,912,000
$326.46 P/Share
|
Jun 09
2025
|
James Edgemond CFO AND TREASURER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+37.36%
|
$1,404,000
$117.76 P/Share
|
Jun 02
2025
|
James Edgemond CFO AND TREASURER |
SELL
Open market or private sale
|
Direct |
12,000
-19.68%
|
$3,900,000
$325.95 P/Share
|
Jun 02
2025
|
James Edgemond CFO AND TREASURER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+37.36%
|
$1,404,000
$117.76 P/Share
|
May 29
2025
|
Paul A Mahon EVP & GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
11,000
-4.18%
|
$3,454,000
$314.94 P/Share
|
May 29
2025
|
Paul A Mahon EVP & GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+10.75%
|
$1,386,000
$126.59 P/Share
|
May 15
2025
|
Paul A Mahon EVP & GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
11,000
-3.15%
|
$3,267,000
$297.17 P/Share
|
May 15
2025
|
Paul A Mahon EVP & GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+18.71%
|
$1,287,000
$117.76 P/Share
|
May 09
2025
|
Tommy G Thompson |
SELL
Open market or private sale
|
Direct |
2,500
-22.77%
|
$762,500
$305.15 P/Share
|
May 09
2025
|
Tommy G Thompson |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+18.55%
|
$437,500
$175.43 P/Share
|
May 01
2025
|
Paul A Mahon EVP & GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
11,000
-2.81%
|
$3,289,000
$299.31 P/Share
|
May 01
2025
|
Paul A Mahon EVP & GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+18.71%
|
$1,287,000
$117.76 P/Share
|
Apr 21
2025
|
Raymond Dwek |
SELL
Open market or private sale
|
Direct |
3,000
-63.16%
|
$855,000
$285.57 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 756K shares |
---|---|
Bona fide gift | 230K shares |
Exercise of conversion of derivative security | 2.3K shares |
---|---|
Open market or private sale | 678K shares |
Sale (or disposition) back to the issuer | 75.9K shares |
Bona fide gift | 232K shares |